Purpose We investigated the role of genetic, physiological, environmental, and epigenetic factors in regulating CYP2A6 expression and nicotine metabolism. Methods Human livers (n = 67) were genotyped for CYP2A6 alleles and assessed for nicotine metabolism and CYP2A6 expression (mRNA and protein). In addition, a subset of livers (n=18), human cryopreserved hepatocytes (n=2), and HepG2 cells were used for DNA methylation analyses. Results Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine Coxidation activity, and affinity for nicotine. Female livers had significantly higher CYP2A6 protein and mRNA expression compared to male livers. Livers exposed to dexamethasone and phenobarbital had higher CYP2A6 expression and activity, however the difference was not statistically significant. Age and DNA methylation status of the CpG island and a regulatory site were not associated with altered CYP2A6.
Introduction
Cytochrome P450 2A6 (CYP2A6) is primarily expressed in the liver and is involved in the metabolism of coumarin and a number of pharmaceuticals including halothane, valproic acid, tegafur, and SM-12502 [1] . In addition, this enzyme can activate procarcinogens such as aflatoxin B1 and tobacco-specific nitrosamines [e.g., 4-methylnitrosoamino-1-(3-pyridyl)-1-butanone and N-nitrosodiethylamine] [1] . Clinically, CYP2A6 is of significance due to its major role in the metabolism of nicotine, the main addictive compound in tobacco [2] . Indeed, multiple genotypic and phenotypic studies have associated variable CYP2A6 with an altered risk for tobacco-related cancers and multiple smoking behaviors such as the risk of being a smoker, the number of cigarettes smoked, and the likelihood of smoking cessation [3] .
In vivo, the majority (70-80%) of nicotine is metabolized to cotinine [4] , and CYP2A6 mediates approximately 90% of this reaction [5, 6] . A common feature among in vivo studies assessing nicotine metabolism and CYP2A6 activity is the large interethnic and interindividual variability observed [7] . Similarly, in human liver microsomes CYP2A6 mRNA, protein, and activity levels have been shown to vary >50-fold [8, 9] .
To date, 37 variant alleles of the CYP2A6 gene have been reported (http://www.cypalleles.ki.se/cyp2a6.htm), many of which result in altered activity accounting for some of the observed variability in CYP2A6-mediated nicotine metabolism [10] . Although several of these alleles have been studied extensively in vivo and in in vitro cDNA expression systems, their effect on CYP2A6 expression in human livers has been assessed by few studies [11, 12] . To our knowledge the effect of CYP2A6 variant alleles on nicotine C-oxidation pharmacokinetic parameters (Vmax and Km) in human livers has not yet been assessed, which is important as some CYP2A6 variants have substratespecific impacts [13] . One aim of this study was to understand the mechanisms by which some of these variants are associated with altered activity in vivo. For example, do CYP2A6 variant alleles associated with lower in vivo activity, particularly for nicotine C-oxidation, encode proteins with lower protein expression, intrinsic activity, and/or apparent affinity for the substrate?
Gender and age have also been shown to influence nicotine pharmacokinetics in vivo. Women have significantly higher rates of nicotine clearance compared to men [14] , while elderly (>65 years) subjects have significantly lower rates of nicotine clearance compared to younger adults (22-44 years) [15] . The higher rates of nicotine clearance among females may be mediated by higher CYP2A6 activity as measured by the established in vivo phenotypic ratio of trans-3′-hydroxycotinine to cotinine (3HC/COT) [16] . Another aim of this study was to investigate whether the gender-and age-related differences in nicotine metabolism were mediated by differences in metabolic factors (i.e., different CYP2A6 expression/activity). Environmental factors could also influence nicotine clearance. For example, grapefruit juice reduces nicotine metabolism by inhibiting CYP2A6 [17] , while drugs such as phenobarbital and dexamethasone induce CYP2A6 [18] .
While CYP2A6 genetic variants, gender, and environment explain some of the variation in CYP2A6 expression and activity, there still remains additional variation [10] . Another source of variation could be epigenetic regulation [19] . Epigenetic processes are heritable, or acquired, modifications of the DNA (i.e., methylation) or its associated proteins such as histones (e.g., histone acetylation) [20] . DNA methylation has been shown to affect the tissuespecific and general expression of several CYPs (e.g., CYP1B1, CYP1A2, CYP2E1, and CYP2W1) [21] . Recently, CYP2A13 was shown to be induced following the cotreatment of NCI-H441 cells with the demethylating agent 5-Aza-2′-deoxycitidine (5-AzaC) and the histone deacetylase inhibitor trichostatin A [22] . Since CYP2A6 shares a 93.5% amino acid sequence identity with CYP2A13 it is possible that CYP2A6 is also epigenetically regulated. CYP2A6 has also been shown to contain a putative important CpG island, which suggests a possible role for DNA methylation in its regulation [21] . Our final aim was to investigate the potential role of DNA methylation in regulating CYP2A6 expression.
In the current study we have used a panel of human liver samples to assess the impact of CYP2A6 genetic variants, gender, age, and exposure to inducers (phenobarbital and dexamethasone) on microsomal CYP2A6 levels and nicotine metabolic parameters (Vmax and Km). In addition, a smaller panel of livers (n=18), human cryopreserved hepatocytes (n= 2), and HepG2 cells was utilized to investigate the potential role of DNA methylation in regulating CYP2A6. In a linear regression model CYP2A6 genotype, gender, and exposure to inducers were associated with altered CYP2A6 expression and activity.
Materials and methods

Human livers
The tissue samples studied here are a compilation from three liver banks: (1) 27 livers from the L-series [5] , (2) 17 livers from the K-series [23] , and (3) 23 livers from the Biocentre in Basel, Switzerland [24] . For clarity and consistency the livers from the Biocentre in Basel will be referred to as the M-series livers. The characteristics and sources of all the livers have been described previously [5, 23, 24] . The ethnic origin of the liver sample donors was unknown, and the cause of death and drug use was known for some of the samples. Mean age of the organ donors was 30 years (range 2-64) and the gender distribution was as follows: 35 males, 26 females, and 6 unknown. Of note, the K-and M-livers were also assessed for CYP2B6 and CYP2D6 protein expression (unpublished data). As a proxy measure for liver quality we did not observe any generalized reduction in the expression of all three CYPs among the different livers.
Cell culture
Human hepatocarcinoma cell line HepG2 cells were generously provided by Dr. David Riddick (University of Toronto, ON, Canada). The HepG2 cells were maintained in a humidified incubator (37°C, 5%CO 2 ) in MEM-α medium (Invitrogen, ON, Canada) supplemented with 10% fetal bovine serum (Invitrogen, ON, Canada). Two lots of human cryopreserved hepatocytes, lot SHM (male, 51 years old, low CYP2A6 mRNA and coumarin hydroxylase activity) and lot VEP (male, 56 years old, high CYP2A6 mRNA and coumarin hydroxylase activity), were purchased from Celsis In Vitro Technologies (MD, USA). The hepatocytes were maintained in InVitroGRO CP medium (Celsis In Vitro Technologies) supplemented with Torpedo Antibiotic Mix (Celsis In Vitro Technologies) on collagen-coated plates (BD Biocoat plates) at 37°C and 5% CO 2 .
Nicotine C-oxidation kinetic assay Liver microsomes were prepared by differential centrifugation as previously described [5] , and protein content was determined by the Bradford protein assay (Bio-Rad Labs, ON, Canada). Nicotine C-oxidation kinetic parameters for the L-livers and two K-livers (K20 and K27) were measured previously by Messina et al. [5] . The remaining K-and M-livers were assayed as previously described [5] , with minor modifications. A range of nicotine concentrations (50, 100, 200, and 500 µM) and 20 min incubation were used. One sample (K27) was assessed using both assays yielding similar results (Vmax=28 vs. 23 [7, 10] , along with other variants of the CYP2A6*1 allele (CYP2A6*1B-*1 K, listed at http://www.cypalleles.ki. se/cyp2a6.htm). Second, in this study CYP2A6*1B did not influence CYP2A6 mRNA, protein, or activity levels. CYP2A6*14 was included in the wild-type group since previous studies [7, 10] and this current study did not find an effect on CYP2A6 expression or activity. To date, only two in vivo studies have assessed the impact of CYP2A6*21; one study showed no effect [29] and the other study associated it with lower activity [10] . Due to the conflicting literature, and the fact that only one liver had a CYP2A6*21 allele, CYP2A6*21 was included in the wild-type group. Of note, the outcomes of all the analyses were not affected by either including or excluding CYP2A6*14 and CYP2A6*21 from the wild-type group.
CYP2A6 protein quantification
The L-livers and two K-livers (K20 and K27) were previously assessed for CYP2A6 protein levels [5] . CYP2A6 protein levels for the remaining K-and M-livers were determined by Western blotting as described previously [5] , with minor modifications. The amount of liver microsomal protein loaded was reduced to 5 µg instead of 30 µg. In addition, the primary (CYP2A6 monoclonal) and secondary (anti-mouse IgG horseradish peroxidase conjugate) antibodies were diluted 1:3,000 and 1:17,000, respectively. All other procedures were identical to those described by Messina et al. [5] . The CYP2A6 immunoreactivity levels of K20 and K27 obtained by Messina et al. [5] were used as a normalization factor to provide a relative scale for all three liver banks. Thus, K20 and K27 were used as internal controls when quantifying CYP2A6 protein levels in the K-and M-livers. Each sample was analyzed a total of 4 times, while the internal controls (K20 and K27) were analyzed 12 times. The CYP2A6 protein levels for K20, assessed by Western blotting, were similar to those reported by Messina et al. [5] , suggesting minimal effects of storage.
Other studies have demonstrated no significant decreases in CYP2A6 microsomal protein levels following 2 to 5 years of storage [25, 26] .
RNA isolation, cDNA synthesis, and relative mRNA quantification
Tissues for only the K-and M-livers (n =40) were available for RNA analyses. Following homogenization of ∼0.1 g of liver tissue, total RNA was isolated with TRIzol reagent (Invitrogen). RNA concentration was determined spectrophotometrically, and the integrity of the 18S and 28S ribosomal bands was confirmed by electrophoresis on a 1.2% agarose gel (OnBio, ON, Canada) stained with ethidium bromide. cDNA from liver RNA was synthesized using 1 µg of total RNA, random hexamers (Invitrogen, RNA guard (Invitrogen), and M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's protocols. Primers for real-time PCR amplification of CYP2A6 and β-actin were as follows: CYP2A6 forward primer (2A6ex2/ 3F): 5′-TCA AAG GCT ATG GCG TGG TA-3′ and reverse primer (2A6ex3/4R): 5′-CGA TAT TGG CGC CGC CA-3′; β-actin forward primer (ACTBFex3): 5′-CAG AGC AAG AGA GGC ATC CT-3′ and reverse primer (ACTBRex4/3): 5′-GGT CTC AAA CAT GAT CTG GGT C-3′. Primer specificity was assessed using BLAST search.
Amplification and fluorescence detection were performed using the ABI 7500 Real-Time PCR system (Applied Biosystems). Real-time PCR amplification was carried out in a mixture (25 µl) containing 1 µl of synthesized cDNA, 12.5 µl of 2× Power SYBR-Green Madter Mix (Applied Biosystems), and 0.3 µM of each primer. Cycling conditions consisted of two activation steps (50°C for 2 min, then 95°C for 10 min) followed by 40 cycles of melting (95°C for 15 s) and annealing/extension (60°C for 1 min). Relative quantifications of CYP2A6 gene expression were obtained by normalizing to β-actin and using the comparative C T method for relative quantification as described by the manufacturer (Real-Time PCR Chemistry Guide, Applied Biosystems). All liver samples were assessed in triplicate.
CYP2A6 DNA methylation
Analysis of the CYP2A6 gene ± 10 kb revealed two CpG sites of potential interest: (1) a CpG dinucleotide within a DR4-like element (−5476 bp) that has been shown to be involved in regulating CYP2A6 expression [30] and (2) a CpG island in intron 2-exon 3 (1656-1889 bp). DNA methylation status of these sites was determined in HepG2 cells, human cryopreserved hepatocytes (n=2), and a subset of liver samples (n=18). The livers selected had extreme CYP2A6 phenotypes (i.e., very high and low CYP2A6 mRNA, protein and activity levels, >50-fold variability), which was not accounted for by genotype as they had none of the CYP2A6 variant alleles investigated.
DNA methylation status of the DR-4 site (8 CpGs) and the CpG island (25 CpGs) was evaluated using sodium bisulfite genomic sequencing. Genomic DNA was modified using the EpiTect Bisulfite kit (Qiagen, ON, Canada) in accordance with the manufacturer's protocol. The modified DNA was then subjected to a two-step semi-nested PCR reaction. Primers used to amplify the first PCR product of the DR-4 site and the CpG island were as follows: DR-4 site forward primer (2A6DRF2): 5′-GGT GAT ATA GTT TGG GTT TGT G-3′ and reverse primer (2A6DRR2): 5′-AAC ATA AAA ATA CCT CAA CAT AC-3′; CpG island forward primer (2A6CpGF4): 5′-GGG AGT TTT TTG GAG TTG T-3′ and reverse primer (2A6CpGR): 5′-ACC TAA TCC CCA TCC C-3′. Primers used to amplify the second PCR product of the DR-4 site and the CpG island were as follows: DR-4 site forward primer 2A6DRF2 and reverse primer (2A6CpG5prR): 5′-ATC TCA ACT CAC TAC AAC CTC TA-3′; CpG-island forward primer (2A6PyroCpGF): 5′-TTT TTT AGG YGT GGT ATT TAG TAA-3′ and reverse primer 2A6CpGR.
Cycling conditions for the first amplification consisted of initial denaturation at 95°C for 3 min; 40 cycles of denaturation at 95°C for 30 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s; followed by a final extension at 72°C for 5 min. The reaction mixture (25 µl) contained 100 ng of modified DNA, 0.2 mM of each dNTP, 0.5 mM MgCl 2 , 1× PCR buffer (Sigma Aldrich, ON, Canada), 1.25 U of Jumpstart Taq DNA polymerase (Sigma Aldrich, ON, Canada), and 0.125 µM of each primer. The cycling conditions for the second PCR reaction were identical to the first, except that the number of cycles was reduced to 25 cycles. The reaction mixture was similar to the first PCR reaction, except that the template was 0.8 µl of 10× diluted first amplification product. In addition, no MgCl 2 was added and the final reaction volume was 50 µl.
PCR products were purified using PureLink PCR purification kit (Invitrogen), cloned into a pGEM-T vector system (Promega, PA, USA), and sequenced using the universal M13-forward primers. An average of eight to ten clones were sequenced per sample. Sequencing was carried out at Functional Biosciences (WI, USA). Specific amplification of CYP2A6 was confirmed by aligning the sequences of the PCR products with CYP2A6, CYP2A7, and CYP2A13 using ClustalW2 (http://www.ebi.ac.uk/ Tools/clustalw2/index.html). The BiQ Analyzer software was used to perform quality control and derive % DNA methylation from the sequencing results [31] .
Statistical analyses
Hardy-Weinberg equilibrium was tested using chi-squared test or Fisher's exact test if five or fewer individuals were in one genotype group. The Kolmogorov-Smirnov and Shapiro-Wilk tests indicated that the phenotypic data (i.e., CYP2A6 mRNA levels, CYP2A6 protein levels, CYP2A6 DNA methylation, Vmax, Km, and Vmax/Km) were not normally distributed. Therefore, nonparametric tests were used in all statistical comparisons unless otherwise stated. Correlation analyses were performed using the Spearman's rank correlation test (r S 2 = rank correlation coefficient squared). Comparisons between two independent groups were carried out using the Mann-Whitney test. A linear regression model was formulated to evaluate which factors were associated with either CYP2A6 protein levels or Vmax. In this case the distribution of the dependent variables (CYP2A6 protein levels or Vmax) was lognormalized for use in the parametric regression analysis. By use of backward selection, the predictors (CYP2A6 genotype, gender, age, and exposure to inducers) were investigated for model inclusion. A predictor was considered to have a significant influence if P≤0.05. The advantage of a linear regression model is that the effect of each predictor on the outcome is tested while controlling for other variables that might also be affecting the outcome. All statistical analyses were performed using SPSS (SPSS, IL, USA, version 15.0 for windows). Graphs were generated using GraphPad Prism (GraphPad Software, CA, USA, version 5.0 for Windows).
Results
Correlations among CYP2A6 mRNA, protein, and nicotine C-oxidation Extensive interindividual variation in CYP2A6 mRNA levels, protein levels, and nicotine-to-cotinine metabolism (Vmax and Km) was observed. Relative CYP2A6 mRNA and protein levels varied more than 1,000-and 100-fold, respectively. The mean ± SD values for Vmax, Km, and Vmax/Km were 30±26 nmol mg protein CYP2A6 mRNA correlated significantly with microsomal CYP2A6 protein (Fig. 1a, r S 2 =0.45, P<0.001). Immunoreactive CYP2A6 protein also correlated significantly with nicotine C-oxidation activity (Vmax) (Fig. 1b , r S 2 =0.37, P<0.001). The correlation between CYP2A6 mRNA levels and Vmax was less robust (n=40, r S 2 =0.15, P=0.02).
The impact of CYP2A6 genetic variation, gender, age, and exposure to inducers on CYP2A6 expression and activity was assessed in two ways. First, consistent with previous literature publications, the effect of each factor was tested on its own. Second, we used a linear regression model in which the effect of each factor was tested while controlling for the other variables that might also be affecting the outcome. This kind of analysis was essential as many of the factors (i.e., genotype, gender, age, and exposure to inducers) were interrelated.
Impact of CYP2A6 genetic variants
The CYP2A6 variants investigated in this study accounted for some of the variability observed in microsomal CYP2A6 protein expression and nicotine pharmacokinetic parameters (Vmax and Km) (Fig. 2) . No livers with CYP2A6*5, *6, *17, *20, *23, *24, *25, *26, *27, *28, or *35 alleles were found. Livers with CYP2A6*2, *4, *9, *12, and *28 were identified and included in the variant group. Genotype frequencies did not deviate significantly from Hardy-Weinberg equilibrium. Liver samples in the wild-type group (n=48) had significantly higher microsomal CYP2A6 protein expression compared to livers in the variant group (n=17) ( Fig. 2a ; 0.90±0.90 vs. 0.40±0.40, P=0.006). However, relative CYP2A6 mRNA levels were similar between the two groups [ Fig. 2b ; wild-type (n=30): 291±298 vs. variant (n=8): 368±431, P=0.8). Of note, the clustering of low CYP2A6 mRNA levels in some wild-type samples (Fig. 2b) is not likely to be related to the integrity of the RNA as these samples had relatively high mRNA levels of certain transcription factors (data not shown). The higher CYP2A6 protein levels among the wild-type group (n=48) were associated with higher nicotine C-oxidation Fig. 1 a, b Correlations among CYP2A6 protein levels, CYP2A6 mRNA levels, and nicotine C-oxidase activity. Open and closed circles denote livers in the wild-type and variant groups, respectively. Triangles denote livers positively genotyped for the duplication allele (CYP2A6*1×2). a CYP2A6 protein and mRNA levels correlated significantly (n=40, r S 2 =0.45, P<0.001). The inset is a representative Western blot. Lane one is cDNA expressed CYP2A6 and the remaining lanes are different liver samples. b CYP2A6 protein levels and nicotine C-oxidase activity correlated significantly (n=67, r S 2 = 0.37, P<0.001) activity (Vmax) compared to the variant group (n=17) ( Fig. 2c; 30±23 
Impact of gender
To minimize any potential bias due to known CYP2A6 genetic variants (Fig. 2) , gender analyses were restricted to livers from the wild-type group. Females (n=20) had significantly higher microsomal CYP2A6 protein levels compared to males (n=26) ( Fig. 3a; 1.3±1.2 vs. 0.6±0.5, P=0.03). In addition, females (n=11) had higher CYP2A6 mRNA levels compared to males (n=17) ( Fig. 3b; 381±289 vs. 194±281, P=0.03). Nicotine C-oxidation activity (Vmax) among females (n=20) was higher, although this did not reach statistical significance compared to that in males (n=26) ( Fig. 3c ; 37±32 vs. 25±12 nmol mg protein
, P=0.3). As expected the apparent Km was similar between females (n=20) and males (n=26) ( Fig. 3d; 57±22 vs. 58±28 µM, P=0.6). Finally, Vmax/Km was not significantly higher among females (n=20) compared to males (n=26) (0.7±0.6 vs. 0.5±0.3 nl mg protein
, P=0.6, data not shown). When the variant livers were included in the gender analyses, Fig. 2 a-d Effect of CYP2A6 variants on CYP2A6 protein levels, CYP2A6 mRNA levels, nicotine C-oxidation activity, and the apparent affinity for nicotine. Open and closed circles denote livers in the wild-type and variant groups, respectively. Triangles denote livers positively genotyped for the duplication allele (CYP2A6*1×2). At least one sample with CYP2A6*1×2 also had other CYP2A6 variants, thus livers with CYP2A6*1×2 were not included in the group (wild-type vs. variant) comparisons. The horizontal line denotes the mean value in each group. Liver samples in the variant group had lower CYP2A6 protein expression (a), similar CYP2A6 mRNA levels (b), lower nicotine C-oxidation activity (Vmax) (c), and higher apparent Km (d) compared to the wild-type group the results remained the same, however the difference in CYP2A6 protein levels was no longer significant (P=0.07).
Impact of age
Among wild-type livers, age did not correlate with either CYP2A6 protein (r S 2 =0.04, P=0.2, n=44) or Vmax (r S 2 = 7.0×10 −4 , P=0.9, n=44). A similar lack of correlation was observed when all the livers were analyzed (Fig. 4) .
Impact of CYP2A6 inducers
Dexamethasone and phenobarbital are known inducers of CYP2A6 [18] . Five liver samples exposed to these drugs (alone or in combination) had higher CYP2A6 protein ( The DR-4 site studied herein contains a total of eight CpG dinucleotides, one of which is located where the nuclear receptor pregnane X receptor (PXR) and the peroxisome proliferator-activated receptor-γ coactivator (PGC-1α) bind and modulate CYP2A6 expression [30] . This specific CpG dinucleotide within the DR-4 site will be referred to as the transcription factor site (TF site). Among human liver samples, the average DNA methylation levels of the total DR-4 site and the specific TF site were 85% (range 65-97%) and 84% (range 66-100%), respectively. Liver samples with extreme CYP2A6 phenotype (i.e., very high vs. low CYP2A6 levels/activity) had similar levels of methylation at both the DR-4 site and the TF site (Fig. 5) . Average DNA methylation level (mean ± 95% CI) of the DR-4 site (85±1.9%) was much higher compared to the methylation at the CpG island (5.0±1.1%) of the same liver samples (n=3). DNA methylation levels (mean ± 95% CI) of the CpG island were similar between liver samples with high (n=1) and low (n=2) CYP2A6 levels/activity (5.3± 2.2 vs. 4.9±1.3%, P=0.9). HepG2 cells, which express very low levels of CYP2A6, had an opposite pattern of methylation compared to human livers (i.e., high methylation in the CpG island and low methylation in the DR-4 and TF sites, Fig. 6 ). The cryopreserved hepatocyte lot with high CYP2A6 mRNA and activity had higher levels of methylation (mean ± 95% CI) at the CpG island (53±5.0%) compared to the sample with low CYP2A6 mRNA activity (5.5±2.5%). The overall methylation (mean ± 95% CI) of the DR-4 site was similar between the two cryopreserved hepatocytes (86±2.8 vs. 89±3.7%). However, the specific CpG dinucleotide within the PXR/ PGC-1α binding site (i.e., TF site) was 0% methylated in the hepatocyte lot with high CYP2A6 mRNA and activity compared to 100% in the lot with low CYP2A6 mRNA and activity.
Discussion
Consistent with previous studies (reviewed in [1] ), we observed substantial interindividual variation in CYP2A6 expression and activity. The significant correlation between CYP2A6 mRNA levels and CYP2A6 protein levels Fig. 4 a, b Impact of age on CYP2A6 protein levels and nicotine Coxidation activity (Vmax). Age did not significantly correlate with either a CYP2A6 protein levels (r S 2 =0.04, P=0.1, n=61) or b nicotine C-oxidation activity (Vmax) (r S 2 =0.01, P=0.4, n=61). Six samples with unknown age were not included in the analyses Fig. 5 a, b DNA methylation status of the DR-4 and TF sites among liver samples with either very high or very low CYP2A6 levels/activity. Each bar represents a single liver sample. The error bars represent the 95% CI in methylation deduced from an average of 8-10 clones per sample. a Male liver samples with very high (n=4) and low (n=6) CYP2A6 levels/activity had similar levels of DNA methylation (mean ± 95% CI) at the DR site (86±4 vs. 88±4%, P=0.2) and the TF site (81±10 vs. 88±7%, P=0.2). b Female liver samples with very high (n=4) and low (n=4) CYP2A6 levels/activity had similar levels of DNA methylation (mean ± 95% CI) at the DR site (83±4 vs. 83±4%, P=0.6) and the TF site (86±8 vs. 80±9%, P=0.3) Fig. 6 Comparison of DNA methylation levels at the CpG island, DR-4 site, and TF site between human liver samples and HepG2 cells. Each bar represents the average methylation level, while the error bars represent the 95% CI in methylation deduced from an average of 8-10 clones per sample. HepG2 cells had significantly higher levels of CpG island DNA methylation (mean ± 95% CI) compared to human livers (n=3) (65±7.4 vs. 5.0±1.1%, P<0.001). In addition, HepG2 cells had significantly lower levels of DNA methylation compared to human livers (n=18) at both the DR-4 site (14±12 vs. 85±1.9%, P< 0.001) and the TF site (14±35 vs. 84±4.2%, P<0.001)
suggests an important role for transcriptional regulation in mediating CYP2A6 protein expression.
One focus of this study was to test the impact of CYP2A6 genetic variants on CYP2A6 expression and nicotine C-oxidation pharmacokinetics in liver tissue. The low gene deletion (CYP2A6*4) allele frequency and absence of alleles predominantly present among individuals of African origin (e.g., CYP2A6*17) [7] suggested that our population is likely of Caucasian origin. Livers in the variant group (CYP2A6*2, *4, *9, *12, and *28) had significantly lower CYP2A6 protein expression compared to the wild-type group. This suggests lower CYP2A6 protein expression as one likely mechanism by which these alleles are associated with lower in vivo CYP2A6 activity. CYP2A6*2 encodes an enzyme that is unable to incorporate heme, making it unstable and more likely to be degraded [32] . CYP2A6*4 is a gene deletion that results in lower transcript levels and consequently lower protein expression. CYP2A6*9 contains an SNP (−48T>G) in the TATA-box that has been associated with lower CYP2A6 mRNA and activity in human livers [12] . CYP2A6*12 is a hybrid allele of CYP2A6 and CYP2A7 in which the 5′ and exons 1 and 2 are of CYP2A7 origin while exons 3 onwards are of CYP2A6 origin. In vitro, COS-1 cells expressing CYP2A6.12 had approximately 50% lower immunodetectable CYP2A6, suggesting that it is an unstable enzyme that is more rapidly degraded [33] . CYP2A6*28 is a haplotype allele (N418D and E419D) that has been associated with lower CYP2A6 activity in vivo [10] . It is possible that the two nonsynonymous SNPs in CYP2A6*28 might result in an unstable enzyme that is more readily degraded, however this remains to be tested. Alternatively, the coding SNPs in CYP2A6*28 might be in linkage disequilibrium with polymorphisms in the gene promoter or within introns that affect transcription and mRNA splicing, and as a result might influence protein expression [10] .
Although the variant group had lower CYP2A6 protein levels compared to the wild-type group, CYP2A6 mRNA levels were similar. It is possible that the variants might be affecting CYP2A6 protein levels at the post-transcriptional stage (e.g., enzyme degradation and/or stabilization) as opposed to affecting transcriptional efficiency. This is thought to occur with CYP2A6*2. On the other hand a correlation between the mRNA and protein levels is expected for CYP2A6*4 and CYP2A6*9. CYP2A6*4 (gene deletion) mRNA should not be amplified in our real-time PCR reaction, while CYP2A6*9 has been associated with reduced transcriptional efficiency [34] . We observed a trend for lower mRNA transcript levels among livers with CYP2A6*12. Of note, our CYP2A6 primers used in the real-time PCR reaction are able to amplify the CYP2A6*12 mRNA. An association of CYP2A6*12 with lower mRNA levels has been previously observed and suggests that this allele is regulated at both the transcriptional and translational level [11] .
Consistent with the correlation between CYP2A6 protein levels and Vmax, the variant group had a lower mean Vmax compared to the wild-type group. In terms of the effect of genotype on the apparent Km (i.e., affinity) for nicotine, the variant group had a significantly higher mean Km value (i.e., lower affinity) compared to the wild-type group. More specifically, samples with CYP2A6*2 or CYP2A6*12 had a relatively higher mean Km values compared to the wild-type, while samples with CYP2A6*4 or CYP2A6*9 had roughly a similar mean Km value compared to the wild-type. This was anticipated since Km is an innate characteristic of an enzyme that is altered by structural changes (e.g., CYP2A6*2 and *12) but not by changes in expression levels (e.g., CYP2A6*4 and *9).
Among wild-type livers, female livers had approximately 2.0-, 1.9-, and 1.5-fold higher levels of CYP2A6 protein, CYP2A6 mRNA, and nicotine C-oxidation activity, respectively, compared to males. Although CYP2A6 expression (mRNA and protein) was significantly higher among female livers, the differences in nicotine C-oxidation activity did not reach statistical significance. This was likely due to the high variability in nicotine C-oxidation activity and the lack of absolute correlation between CYP2A6 levels and nicotine Coxidation activity. Our findings suggest that the higher in vivo nicotine clearance rates [14] and CYP2A6 activity [16] observed among females are likely due to higher hepatic CYP2A6 protein expression. Pregnancy and oral contraceptive use have been shown to further increase the rates of nicotine clearance suggesting a hormonal effect on CYP2A6 [35] . Indeed, CYP2A6 is induced by estrogen in an estrogen receptor-alpha (ER-α)-dependent manner [36] . The lack of an association between gender and CYP2A6 protein expression in previous studies [5, 8, 37] is likely due to the fact that these studies did not genotype for CYP2A6 variants. As we have demonstrated, CYP2A6 genetic variants have a significant effect on CYP2A6 expression, which might mask gender differences.
There was no significant correlation between age and CYP2A6 expression/activity. This is consistent with previous human liver studies [8, 37] . In contrast, an in vivo nicotine pharmacokinetic study found that elderly (>65 years) subjects had significantly lower rates of nicotine clearance compared to younger adults (22-44 years) [15] . It is possible that we did not find an association between age and CYP2A6 levels as our age range was below that of 65 years; our oldest liver was from a 64-year-old organ donor. Alternatively, the lower in vivo nicotine clearance rates among elderly individuals could be due to changes in other factors associated with age such as decrease in liver mass and blood flow [38] .
When all the factors (CYP2A6 genetic variants, gender, age, and exposure to inducers) were included in a model to predict variability in CYP2A6 protein levels, only CYP2A6 variants and gender were significant predictors. The final model accounted for only 19% of the observed variability in CYP2A6 levels, suggesting there still remains a large amount of variability that is unaccounted for. We cannot rule out the contribution of other unidentified genetic variants. In addition, variability in the expression of nuclear transcription factors that regulate cytochrome P450 (CYP) expression could also affect CYP2A6 levels. For example, CYP2A6 mRNA levels have been shown to significantly correlate with mRNA levels of the nuclear receptors CAR and HNF4-α [39] . We were able to capture a smaller amount of variation (11%) in nicotine C-oxidation activity (Vmax). This is likely due to the fact that other enzymes (CYP2B6) might also play a small role in this metabolic pathway [40] . In addition, variation in CYP activity could also be mediated by variation in the activity of CYP cofactors (e.g., NADPHcytochrome P450 oxidoreductase) [41] .
In our pilot epigenetic investigation we did not observe a prominent role for DNA methylation in regulating CYP2A6 expression in human livers. Nonetheless, two interesting but preliminary results were observed. First, HepG2 cells, which express low levels of CYP2A6, had an opposite pattern of DNA methylation compared to liver cells, suggesting a possible role for DNA methylation in reducing CYP2A6 expression within this cell line. We treated the HepG2 cells with the demethylating agent 5-AzaC using a previously published paradigm [42] but did not observe any changes in its DNA methylation status. The second interesting observation was that the cryopreserved hepatocyte lot with high CYP2A6 activity was fully demethylated at the TF site while the low activity lot was fully methylated. The TF site is a CpG dinucleotide within a DR-4-like element to which PXR/PGC-1α is thought to bind and modulate CYP2A6 expression [30] . Thus, the lack of methylation might make the site more accessible to the transcription factors resulting in higher expression/activity. It is important to note that the lack of an association between CYP2A6 expression and DNA methylation among the human livers is not evidence that CYP2A6 is not epigenetically regulated. Our investigation was limited to a small number of livers and only two DNA regions; there are many CpG-dense sites within the CYP2A6 gene that might be involved in epigenetic regulation. Recently, the allele specific expression of CYP2A7 was reported to be dependent on allele haplotype sequence and its methylation status, suggesting an interesting combinatorial effect between sequence variation and methylation status [43] . In addition, CYP2A13 expression has been shown to be induced by epigenetic modulators [22] . Given that CYP2A6 is highly homologous to CYP2A7 (96.5% identity) and CYP2A13 (93.5% identity), it is likely that CYP2A6 might be epigenetically regulated, perhaps at other loci.
In conclusion we have shown that CYP2A6 genetic variants markedly influence the expression of CYP2A6 and nicotine pharmacokinetics in human liver microsomes. Moreover, our results indicate that the higher in vivo nicotine clearance rates and CYP2A6 activity observed among females are likely due to higher hepatic CYP2A6 protein expression. Finally, our study suggests that even with our current state of knowledge, unexplained variation in CYP2A6 expression and activity still remains. Identifying sources of interindividual variation will help refine the relationship between CYP2A6 and phenotypic measures and improve our understanding of the influence of CYP2A6 on clinical outcomes.
